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SUMMARY
A large body of evidence that has accumulated over the past decade strongly supports
the role of inflammation in the pathophysiology of human epilepsy. Specific inflamma-
tory molecules and pathways have been identified that influence various pathologic
outcomes in different experimental models of epilepsy. Most importantly, the same
inflammatory pathways have also been found in surgically resected brain tissue from
patients with treatment-resistant epilepsy. New antiseizure therapies may be derived
from these novel potential targets. An essential and crucial question is whether target-
ing these molecules and pathways may result in anti-ictogenesis, antiepileptogenesis,
and/or disease-modification effects. Therefore, preclinical testing inmodelsmimicking
relevant aspects of epileptogenesis is needed to guide integrated experimental and
clinical trial designs. We discuss the most recent preclinical proof-of-concept studies
validating a number of therapeutic approaches against inflammatory mechanisms in
animal models that could represent novel avenues for drug development in epilepsy.
Finally, we suggest future directions to accelerate preclinical to clinical translation of
these recent discoveries.
KEY WORDS: Inflammation, Immune response, Drug development, Anti-ictogen-
esis, Antiepileptogenesis, Diseasemodification, Epilepsy.
There is an urgent need for the development of new drugs
for patients with drug-resistant epilepsy. In particular, anti-
epileptogenesis or disease-modifying therapies for prevent-
ing or delaying the onset of the disease are still lacking. In
the last decade, an increasing body of clinical and experi-
mental evidence supports the role of inflammation in the
pathophysiology of epilepsy.1 Different inflammatory
molecules and pathways have been shown to significantly
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contribute to the mechanisms of seizure generation and pro-
gression in different experimental models.2–6
Herein we summarize presentations concerning targets
and treatments validated in experimental models—i.e.,
cyclooxygenase-2 (COX-2), prostaglandin (PG) EP2 recep-
tor, monoacylglycerol lipase (MAGL), interleukin-(IL)1b,
high mobility Group Box 1 (HMGB1)/Toll-like receptor
(TLR) signaling, P2X7 receptor, immunoproteasome, mam-
malian target of rapamycin (mTOR), transforming growth
factor-b (TGF-b), metalloproteinases, and chemokines;
Fig. 1. We discuss strategies related to target validation,
controversies and open questions that may hopefully help to
improve research efforts for novel drug development and
foster more coordinated experimental and clinical trial
designs (Table 1).
COX-2, PGE2, and MAGL
(Wolfgang L€oscher, Raymond Dingledine, Gaetano Ter-
rone)
The enzyme COX-2, which catalyzes the production of
prostaglandins, is induced rapidly and strongly in the brain
after various insults, thus contributing to brain inflamma-
tory processes involved in the long-term consequences of
such insults. The use of selective COX-2 inhibitors has
been considered as a novel approach for antiepileptoge-
nesis or disease modification after brain injuries such as
head trauma, cerebral ischemia, or status epilepticus (SE).7
Accordingly, conditional ablation of COX-2 limited to
forebrain neurons is neuroprotective and reduces brain
inflammation after SE.8 L€oscher discussed previously
reported conflicting results related to prophylactic admin-
istration of different COX-2 inhibitors after SE in rodents.
Jung et al.9 showed that prolonged administration of the
COX-2 inhibitor celecoxib after pilocarpine-induced SE in
rats prevents neuronal damage in the hippocampus and
reduces incidence, frequency, and duration of spontaneous
recurrent seizures, indicating an antiepileptogenic or
Figure 1.
Schematic representation of the
cascade of inflammatory processes in
which neurons, astrocytes, microglia,
and endothelial cells are involved.
Several inflammatory targets have
been validated in experimental
models (i.e., cyclooxygenase-2,
prostaglandin EP2 receptor,
interleukin-1b, HMGB1/Toll-like
receptor signaling, P2X7 receptor,
immunoproteasome, mTOR, TGFb,
metalloproteinases (MMPs),
chemokines). The complement
activation (not shown) could also
contribute to a sustained
inflammatory response,1,3 deserving
further investigation as a potential
target of therapy.
Epilepsia ILAE
Key Points
• Inflammatory molecules have been identified in exper-
imental models of epilepsy and surgically resected
brain tissue from treatment-resistant epilepsy
• Targeting these pathways results in anti-ictogenesis,
antiepileptogenesis, and/or disease- modifying effects
• Therapeutic approaches against inflammatory mecha-
nisms could represent novel avenues for drug develop-
ment in epilepsy
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Table 1. Overview of targets and treatments validated in experimental models
Target/pathway Experimental models Treatment/drugs Effect References
Cox-2 Pilocarpine-induced SE
Sprague-Dawley rats
Electrically-induced SE
Sprague-Dawley rats
Pilocarpine (+LPS)-induced SE
Sprague-Dawley rats
Pilocarpine (+LPS)-induced SE
Wistar rats
Absence seizuresWAG/Rij rats
Pilocarpine-induced SE C57BL/6 mice
COX-2 inhibitor celecoxib
COX-2 inhibitor SC58236
COX-2 inhibitor parecoxib
COX-2 inhibitor CAY 10404
COX-2 inhibitor etericoxib
COX-2 neuronal conditional
KO C57BL/6 mice
Antiepileptogenic,
disease-modifying
No antiepileptogenic
No antiepileptogenic,
disease-modifying
No antiepileptogenic,
disease-modifying
Disease-modifying
Disease-modifying
9
10
11
12
13
8
Cox 2 + IL-1b Pilocarpine (+LPS)-induced SE
Wistar rats
COX-2 inhibitor CAY 10404+
recombinant Interleukin-1
antagonist
Disease-modifying 12
EP2/ PGE2 receptor Organophosphorus induced SE
Sprague-Dawley rats
Pilocarpine-induced SE C57BL/6 mice
EP2 competitive antagonist
TG6-10-1
EP2 competitive antagonist
TG6-10-1
Disease-modifying
Disease-modifying
19,20
18
Monoacylglycerol
lipase
Intraamygdala kainic acid induced SE
C57BL/6 mice
CPD-4645 (MAGL inhibitor) Disease-modifying Terrone G, Pauletti A,
Salamone A, Villa BR,
Guilmette E, Piro J,
Samad T, Vezani A,
unpublished
observations
IL-1b Bicuculline induced seizures
C57BL/6 mice
Pilocarpine-induced SE
Sprague-Dawley rats
Rapid kindling model
Electrically-induced SE/
pilocarpine-induced
SEWistar rats/Sprague-Dawley rats
Genetic absence epilepsy
(GAERS rats);
kainic acid–induced seizures;
electrically-induced SE/
pilocarpine-induced SE; kindling
model
Sprague-Dawley rats
Human recombinant IL-1
receptor antagonist (anakinra)
VX-765 (caspase-1 inhibitor)
Anticonvulsive
Anticonvulsive
Antiepileptogenic
No antiepileptogenic or
disease-modifying
Anticonvulsive/
Antiepileptogenic
83
84
85
86
86-90
TLR4 or HMGB1 Kainic acid–induced seizures
C57BL/6 mice
HMGB1 (BoxA) and TLR4
(Lps-Rs) antagonists
Anticonvulsive 91
IL-1b/HMGB1 Kainic acid–induced seizures
C57BL/6 mice
Anakinra (IL-1 receptor
antagonist),
BoxA (HMGB1 antagonist)
Disease-modifying 25
IL-1b/miR146 Kainic acid–induced seizures
Intraamygdala
kainic acid induced SE C57BL/6 mice
miR146a-mimic Anticonvulsive and
disease-modifying
25
P2X7 receptor intra-amygdala kainic acid-induced
status epilepticus C57BL/6 mice
P2X7 receptor antagonist
JNJ-47965567
Disease-modifying 37
Immunoproteasome 4-aminopyridine-induced
seizure-like eventsWistar rats
b5i immuno-subunit inhibitor Anticonvulsive 50
mTOR Kainic acid–induced SE
Electrically-induced SE/
Kainic acid–induced
SE Sprague-Dawley rats
Rapamycin Anticonvulsive/
Antiepileptogenic
Anticonvulsive and
disease-modifying
92
54-56
TGF b Rat model of vascular injury/
albumin-induced
seizuresWistar rats
Losartan (TGF-b signaling
blocker)
Antiepileptogenic 64
Metalloproteinases kindling-induced seizures
Sprague-Dawley rats
Doxycycline (broad
spectrumMMP inhibitor)
Anti-ictogenic 68
Continued
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disease-modifying effect in this post-SE model of temporal
lobe epilepsy. In apparent contrast to the study of Jung
et al.,9 Holtman et al.10 did not find any evidence of antie-
pileptogenic, disease-modifying, or neuroprotective effects
of prolonged treatment with another COX-2 inhibitor,
SC58236, after electrically induced SE. Similar experi-
ments were performed by Polascheck et al.,11 using pare-
coxib, a prodrug of the highly potent and selective COX-2
inhibitor valdecoxib, because celecoxib has been reported
to also exert COX-2 independent actions. Using an electri-
cal model of SE, L€oscher et al. partially confirmed the
findings of Jung et al.9 in the pilocarpine model, thereby
allowing evaluation of which experimental factors may
affect the outcome of such studies. Prophylactic treatment
with parecoxib prevented the SE-induced increase in
PGE2 and reduced neuronal damage in the hippocampus
and piriform cortex. However, the incidence, frequency, or
duration of spontaneous seizures developing after SE, or
the behavioral and cognitive alterations associated with
epilepsy, was not affected by parecoxib. Only the severity
of spontaneous seizures was reduced, suggesting a disease-
modifying effect. These results substantiated that COX-2
contributes to neuronal injury developing after SE, but
inhibition of COX-2 alone does not appear to provide an
effective strategy to modify epileptogenesis. This implies
that neuroprotective strategies alone after SE are unlikely
to affect epileptogenesis. In view of the complexity of the
inflammatory alterations after brain insults such as SE, it is
more likely that a multi-targeted combination of different
anti-inflammatory drugs is needed for efficient control of
the pathologic inflammatory cascade. Indeed, Kwon
et al.12 studied combinations of anti-inflammatory drugs in
the pilocarpine model in developing rats (2–3 weeks of
age) and found that none of these drugs affected epilepsy
when administered alone, whereas the blockade of IL-1
receptor type 1 (IL-1R1) using anakinra and concomitant
COX-2 inhibition greatly reduced the development of
spontaneous recurrent seizures and limited the extent of
CA1 injury and mossy fiber sprouting. However, treat-
ment started shortly before SE induction, so that it is not
clear whether the effects of treatment were due to initial
insult modification or to genuine antiepileptogenesis.
More recently, Citraro et al.13 reported that early long-
term treatment with the COX-2 selective inhibitor
etoricoxib reduced by ~40% the development of sponta-
neous absence seizures in WAG/Rij rats, a recognized
animal model of absence epilepsy. The latter finding
could either indicate that COX-2 is more critical in
epileptogenesis underlying absence epilepsy than in tem-
poral lobe epilepsy or, more likely, that post-SE models
of epilepsy are too severe to disclose antiepileptogenic
effects of COX-2 inhibitors.
Notably, several COX-2 inhibitors have been withdrawn
from the market due to cardiac events.14 Therefore, an alter-
native strategy to increase target selectivity with a milder
adverse event profile, might be achieved by a drug acting on
a downstream prostanoid receptor. Because PGE2 is a major
product of COX-2 in the brain, and two of its receptors, EP1
and EP2, have been implicated in neuronal injury and
inflammation in other disorders,15 Dingledine et al. focused
on these two prostanoid receptors. A higher dose of sys-
temic kainate was required to produce SE in EP1 knockout
Table 1. Continued.
Target/pathway Experimental models Treatment/drugs Effect References
Chemokines Kainic acid–induced SE
Sprague-Dawley rats
Kainic acid–induced SE +
LPS C57BL/6 mice
RNAi against CCR5
CCR2 antagonist (RS102895);
transcription inhibitor
(bindarit)
Disease-modifying
Anticonvulsive
71
76
Peripheral immune
cells
Acquired and genetic
epilepsy models
C57BL/6 mice
PLG nanoparticles
combined with
autologous natural
regulatory T cells
Inhibiting brain invasion of
CCR2+monocytes
Effects on
epileptogenesis: to be
determined
Effects on
epileptogenesis:
to be determined
Koh S,
unpublished
observations
SE, status epilepticus. Celecoxib, Parecoxib, Etoricoxib: COX-2 inhibitors, nonsteroidal anti-inflammatory drug used for pain management; SC5823, CAY
10404: COX-2 inhibitors with anti-inflammatory properties. Human recombinant IL-1 receptor antagonist (anakinra): nonsteroidal anti-inflammatory drug used to
treat autoinflammatory diseases. TG6-10-1: prostaglandin E2 receptor 2 competitive antagonist with anti-inflammatory properties. CPD-4645: monoacylglycerol
lipase (MAGL) inhibitor with anti-inflammatory properties. VX-765: caspase-1 inhibitor (ICE/caspase-1 subfamily) with anti-inflammatory properties. BoxA, High-
Mobility Group Box-1 (HMGB1) antagonist of liposaccharide from the photosynthetic bacterium Rhodobacter sphaeroides (LPS-Rs), Toll-like receptor 4 (TLR4)
antagonist with anti-inflammatory properties. miR146a-mimic: small, chemically modified double-stranded RNA that mimic endogenous miR146a with anti-inflam-
matory properties. JNJ-47965567: high affinity P2X7 antagonist with anti-inflammatory properties. b5i/ LMP7 immuno-subunit inhibitor: immunomodulatory prop-
erties. Rapamycin: mammalian target of rapamycin (mTOR) inhibitor with immunosuppressant /immunomodulatory properties, originally applied as an
immunosuppressant, blocking T-cell activation, and has been in use to prevent kidney graft rejection; mTOR inhibitors are used in the cancer therapy93 and in the
management of patient with tuberous sclerosis complex (TSC;94). Losartan: selective, competitive angiotensin II receptor type 1, a commonly used antihyperten-
sive, also shown to antagonize TGFb signaling. Doxycycline: a broad-spectrum antibiotic of the tetracycline used to treat bacterial infections, which has been shown
to have anti-inflammatory properties and to act as broad spectrum metalloproteinase (MMP) inhibitor. CCR5 (CC chemokine receptor). RS102895: a spiropiperi-
dine compound that acts as a CCR2 (CC chemokine receptor) antagonist with anti-inflammatory properties. Bindarit: inhibitor of CCL2 synthesis with anti-inflam-
matory properties. Biodegradable nanoparticles formulated from the FDA-approved biopolymer poly(lactide-co- glycolide) (PLG) with anti-inflammatory
properties.
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mice (KO) compared to wild-type (WT) controls, but EP1
KO mice that did experience typical SE had reduced hip-
pocampal neurodegeneration and a blunted inflammatory
response.16 Because this is a global KO, the location of the
responsible EP1 receptors is, of course, unspecified by this
experiment. Coexpression of recombinant EP1 and kainate
receptors in cell cultures demonstrated that EP1 receptor
activation potentiates heteromeric but not homomeric kai-
nate receptors via a second messenger cascade involving
phospholipase C, calcium, and protein kinase C. Turning to
EP2, Dingledine et al. used high-throughput screening and
medicinal chemistry to develop a small molecule acting as
an EP2 competitive antagonist that is potent (Schild
Kb = 18 nM for human EP2), selective (10- to >500-fold
over other prostanoid receptors as well as 38 other receptors,
enzymes, and channels), brain-permeant (brain/
plasma = 0.8–1.6), orally available, and with sufficient
plasma half-life (1.6–2.5 h) in mouse and rat to be useful
for in vivo studies.17–19 Brief (2–3 day) treatment with the
EP2 antagonist beginning 2–4 h after SE onset, during the
time in which neuronal COX-2 is induced, appeared to fully
replicate the effects of neuron-selective conditional COX-2
ablation. Thus mice or rats treated with the EP2 antagonist
showed neuroprotection and less neuroinflammation, and
blood–brain barrier (BBB) permeability function was pre-
served. Moreover, the typical development of a deficit in
the novel object recognition test was prevented in rats trea-
ted briefly with the EP2 antagonist after SE onset.20 This
suggests that much of the morbidity associated with COX-2
induction after SE is mediated by the activation of EP2, and
possibly EP1, by COX-2 derived PGE2. Delayed inhibition
of EP2 could therefore represent a viable adjunctive treat-
ment for alleviating the deleterious consequences of SE. In
studies of cultured microglia, EP2 has been shown to act as
an immunomodulator of microglial activation, with much of
its effects being mediated through ePAC (cAMP-regulated
guanine nucleotide exchange factors) rather than protein
kinase A.21,22 Excessive EP2 activation can eventually kill
activated microglia in vitro and thus might participate in
resolution as well as generation of inflammation.
Terrone G, Pauletti A, Salamone A, Villa BR, Guilmette
E, Piro J, Samad T, and Vezzani A provided evidence sup-
porting that MAGL is a potential target for drug develop-
ment in epilepsy, in particular for the treatment of drug-
refractory SE.23 MAGL is a key enzyme in the hydrolysis of
the endocannabinoid 2-arachidonoylglycerol (2-AG) and
represents the major brain source of arachidonic acid (AA)
and eicosanoids.24 The authors showed that the severity and
duration of benzodiazepine-refractory SE, and the conse-
quent cell loss and cognitive deficits, were significantly
reduced in mice treated with a potent and selective irre-
versible MAGL inhibitor, and that these therapeutic effects
were potentiated by the ketogenic diet (KD). Notably, when
MAGL was inhibited in KD-fed mice, SE was virtually
abolished with immediate effect. Moreover, KD itself,
although not affecting SE, prevented the hippocampal cell
loss. Based on these positive results, they are further evalu-
ating the mechanisms of therapeutic action of MAGL inhi-
bition to determine if it is mainly mediated by 2-AG
accumulation, thereby activating CB1 receptors, or by
reduction of arachidonic acid availability to COX-2, thus
providing anti-inflammatory effects (Terrone G, Pauletti A,
Salamone A, Villa BR, Guilmette E, Piro J, Samad T, Vez-
zani A, unpublished obersvations).
IL-1R1//TLR4 Signaling,
microRNAs, P2X7 Receptors and
Immunoproteasome
(Annamaria Vezzani, Sebastian Bauer, Braxton A. Nor-
wood, Eleonora Aronica, David C. Henshall, Michele
Mishto)
The activation of the IL-1R1 and TLR4 signaling pathways
by their endogenous ligands IL-1b and HMGB1, respec-
tively, is pivotal for the generation of neuroinflammatory
responses during seizures or after epileptogenic injuries, and
their pharmacologic blockade or genetic inactivation results
in powerful anticonvulsive effects.5 These pathways are con-
comitantly activated during epileptogenesis, thus likely
requiring a rational drug combination for their effective
blockade. Bauer et al. performed longitudinal cerebral micro-
dialysis monitoring of hippocampal cytokine release in exper-
imental epileptogenesis, detecting consistent elevations of
IL-1b, and Norwood provided evidence of endosomal TLR
dysregulation in experimental epilepsy (Norwood BA,
unpublished observations). Vezzani et al. studied whether a
combination of anti-inflammatory drugs targeting the icto-
genic IL-1b-IL-1R1 and HMGB1-TLR4 proinflammatory
signals affects spontaneous seizure onset and disease progres-
sion in two rodent models of acquired epilepsy. They used
two different schedules of intervention: male adult Sprague-
Dawley rats exposed to electrical SE were given the drugs
during the prodromal phase of epilepsy, whereas C57BL6
adult male mice exposed to intra-amygdala kainate-induced
SE were treated after the onset of the disease (i.e., after the
first two unprovoked seizures). Rats were injected daily for
7 days with a combination of anakinra (IL-1 receptor antago-
nist), BoxA (HMGB1 antagonist), and ifenprodil (NR2B-
NMDA receptor antagonist) starting 1 h post-SE. Mice were
injected daily for 7 days with a combination of VX-765 (IL-
1b biosynthesis inhibitor) and cyanobacterial LPS (TLR4
antagonist) starting after the onset of epilepsy in each mouse.
EEG recording (24/7) was performed from SE induction until
the onset of spontaneous seizures, and for an additional
4 weeks in the chronic epilepsy phase. The combined treat-
ments blocked seizure progression occurring in this model
over 3 months post-SE, leading to a reduction in the fre-
quency of spontaneous seizures by 70–90% in the chronic
epilepsy phase both in rats and mice as compared to
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corresponding vehicle-treated SE-exposed animals.25 When
drugs were given before the onset of epilepsy, they addition-
ally reduced neurodegeneration in forebrain and improved
memory deficits in epileptic animals. Similar therapeutic
effects were attained when treating electrical SE-exposed rats
with a combination of drugs targeting oxidative stress mecha-
nisms.25
The targeting of IL-1R/TLR4 signaling has been
attempted also by epigenetic intervention with microRNAs
(miRNAs). Molecular biology has been revolutionized by
the discovery of these small regulatory molecules that regu-
late gene expression. Several miRNAs have been found in
human brain to have crucial roles in a wide range of normal
biologic processes, including inflammation.26,27 In particu-
lar, Aronica et al. showed an upregulation of miRNAs
involved in the modulation of the IL-1R/TLR pathway,
including miR146a, miR21, and miR155, during epilepto-
genesis.28 These miRNAs were also shown to be deregu-
lated in different human epilepsy-associated pathologies
including hippocampal sclerosis, malformations of cortical
development, and glioneuronal tumors.29–31 Of interest,
tumor and peritumoral miR146a expression was negatively
correlated with frequency of seizures.30 The expression of
miR21, miR146a, and miR155 in astrocytes within epilepto-
genic brain lesions points to the role of these cell types as
both source and targets of these miRNAs. IL-1b stimulation
strongly induced miR146a extracellular release in human
astrocytes in culture, and IL-1b signaling was differentially
modulated by overexpression of miR155 or miR146a,
resulting in proinflammatory or antiinflammatory effects,
respectively.31 It is likely that expression of miR146a in
astrocytes may represent a homeostatic mechanism aimed
at counteracting the inflammatory response triggered by
either IL-1b or other proinflammatory miRNAs.
To provide a preclinical proof-of-concept evidence of a
therapeutic treatment targeting this miRNA, Iori et al.25
tested the effect of a synthetic oligonucleotide analog of
miR-146a in murine models of acute seizures and chronic
epilepsy. Intracerebroventricular injection of a synthetic
miR-146a mimics significantly reduced neuronal excitabil-
ity and acute seizure susceptibility. Moreover, the mimic
stopped the disease development when injected in mice
after the epilepsy onset, and reduced cell loss and improved
memory deficit when given shortly after the epileptogenic
event. These therapeutic effects were similar to those
attained with anti-inflammatory drug intervention against
the IL-1R1 and TLR4 receptors, and were associated with
broad modifications in immune/inflammatory pathways in
the brain.25
Another key driver of neuroinflammation is the P2X7
receptor, an ATP-gated ionotropic purinergic receptor
expressed predominantly in microglia, and also in presy-
naptic nerve terminals. Henshall reported that activation of
these receptors results in cell depolarization and activation
of signaling pathways that promote microglial activation
and inflammasome-mediated IL-1b release leading to
acute and chronic neuroinflammation.32,33 Previous studies
found increased expression of the P2X7 receptor in experi-
mental and human epilepsy, and antagonists of this recep-
tor have been reported to reduce seizure severity in certain
models of SE.34–36 In recent studies, a reporter mouse
expressing enhanced green fluorescent protein driven by
the P2rx7 gene promoter has been used to identify the cell
types involved. These studies show that the receptor is
expressed by neurons as well as by microglia in mice that
develop epilepsy after intra-amygdala kainic acid–induced
SE.37 Intracellular recordings and analysis of synaptoneu-
rosomes indicated enhanced agonist-evoked and altered
calcium responses in hippocampal neurons from epileptic
mice. Increased P2X7 receptor levels were observed in
hippocampus resected from patients with pharmacoresis-
tant temporal lobe epilepsy, as well as in patients with
focal cortical dysplasia.37,38 Moreover, twice-daily sys-
temic injections of the centrally available, potent, and
specific P2X7 receptor antagonist, JNJ-47965567 (30 mg/
kg), significantly reduced spontaneous seizures during con-
tinuous video-EEG monitoring. Of interest, the sponta-
neous seizure rate did not return to baseline during a
relatively short monitoring after drug washout. The hip-
pocampus of epileptic mice treated with the P2X7 receptor
antagonist showed markedly reduced microgliosis and
astrogliosis. These latest studies suggest that targeting the
P2X7 receptor has anticonvulsant and possibly disease-
modifying effects in experimental epilepsy.37
A potential novel target that was discussed by Mishto is
the proteasome, the core of the ubiquitin proteasome sys-
tem, which degrades the large majority of the cytoplasm
proteins and is thus involved in several metabolic pathways
including synaptic protein metabolism.39 The incorporation
of the three inducible subunits b1i, b2i, and b5i into newly
formed proteasomes results in the generation of the so-
called immunoproteasome. This proteasome isoform is nor-
mally induced during inflammation, has altered polypeptide
degradation dynamics compared to the standard proteasome
isoform,40–42 and is endowed of pathophysiologic functions
related to immunity and inflammation responses.43 In
healthy young human brain, the expression of the immuno-
proteasome is almost absent.43 On the contrary, it is
expressed in the brain of elderly and patients with different
neurologic diseases with an inflammatory component such
as Huntington disease, Alzheimer disease, multiple sclero-
sis,44–47 as well as with temporal lobe epilepsy and malfor-
mations of cortical development.48,49 In agreement with the
latter observations, the b5i immuno-subunit expression is
induced also in experimental epilepsy, and its selective
pharmacologic inhibition reduced the incidence and delayed
the occurrence of 4-aminopyridine–induced seizure-like
events evoked in acute rat hippocampal/entorhinal cortex
slices.50 These effects were stronger in slices obtained from
epileptic versus normal rat brain, likely due to the prominent
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b5i subunit induction in neurons and glia in diseased tissue.
TLR4 signaling activation is likely involved in the tran-
scriptional induction of b5i, an effect that was independent
on promoter methylation.50 The proteasome subunit expres-
sion is also induced by IL-1b in human astrocytes in vitro
and is negatively regulated by treatment with the
immunomodulatory drug rapamycin, an inhibitor of the
mTOR pathway.49 How the immunoproteasome could have
a pro-ictogenic effect is unknown. It could have either a spe-
cific role in the regulation of synaptic density or could act
as enhancer of inflammatory milieu, as demonstrated for
other neurological diseases.47,51 Of note, the immunopro-
teasome could regulate (neuro)inflammation not only as
intracellular protease but also in the extracellular space.
There, it could regulate pro-inflammatory functions of
cytokines, as recently demonstrated for osteopontin in the
multiple sclerosis context.52 Therefore, the immunoprotea-
some might be considered as a therapeutic target for phar-
macoresistant epilepsies as it is already under investigation
for cancers, Alzheimer’s disease, and other diseases.47
mTOR, TGF-beta, and
Metalloproteinases as Targets
for Treatment
(Jan A. Gorter, Daniela Kaufer, Michael O. Poulter)
Recent observations show that inhibition of the mTOR
pathway affects SE-induced epileptogenesis in rat models
of temporal lobe epilepsy.53,54 Testing the hypothesis that
the immunosuppressant rapamycin can also reduce brain
inflammation after SE, Gorter reported that a 6-week treat-
ment with rapamycin (6 mg/kg, i.p., first injection starting
at 4 h post-SE induction) reduced seizure frequency during
treatment and resulted in decreased neuronal death, mossy
fiber sprouting, and BBB leakage. Remarkably, hippocam-
pal microglia and astroglia activation, which was used as an
indicator of inflammation, was not altered compared to
vehicle-injected rats, suggesting that the suppressive effect
on seizures was not directly linked to reduction of inflam-
mation.54 Too get more insights into the time course of BBB
damage and hippocampal inflammation, magnetic reso-
nance imaging (MRI) was performed in rats using gadobu-
trol as a contrast agent, and, in a separate group of rats, real-
time quantitative polymerase chain reaction (RT-qPCR) of
hippocampal tissue was performed to measure markers of
inflammation.54,55 These experiments showed that both
BBB leakage and inflammation were initially increased dur-
ing rapamycin treatment in SE rats compared to vehicle-
treated rats, but recovered to a greater extent after the first
week following SE in drug- than in vehicle-treated rats. The
fact that inflammation markers were not significantly
altered at 6 weeks after SE in rapamycin-treated rats as
compared to vehicle animals, implies that the drug reduces
inflammation over time (Gorter JA, Drion C, Aronica E,
Iyer A, Kooijman L, Chameau P, van Vliet EA, unpublished
observations). Moreover, the data suggest that rapamycin
can modulate BBB integrity depending on the physiologic
condition of BBB during epileptogenesis.
To find out whether rapamycin reduces seizure frequency
via an antiseizure effect or an antiepileptogenic effect, addi-
tional experiments were performed.56 In the first experi-
ment, rapamycin treatment was stopped 3 weeks post-SE,
and subsequent seizure development was monitored using
hippocampal EEG recordings. It was found that the daily
seizure reduction measured during treatment was lost after
discontinuation of rapamycin. Nevertheless, the rate of sei-
zure development with the “stop-treatment” protocol was
slower than in rats that had received a vehicle treatment or
historical post-SE groups, suggesting a seizure-modifying
effect of this treatment.54
In the second experiment, rats that were treated with rapa-
mycin during the chronic epilepsy phase, showed a reduc-
tion in the number of daily spontaneous seizures.
Accordingly, inhibition of mTOR by rapamycin has been
shown to suppress established chronic seizures in the pilo-
carpine rat model of epilepsy.57 Elimination of rapamycin
from the bloodstream was extremely slow, with the drug
being detectable 1 month after the last injection in post-SE
rats.56 Of interest, in mice, elimination of rapamycin from
the brain has been shown to be much slower than from
blood/plasma.58
Overall, these data suggest that the effect of rapamycin
on seizure development could be due at least in part to a
symptomatic seizure-suppressing effect. During rapamycin
treatment in post-SE rats, the rat’s body weight was strongly
reduced versus vehicle, even when rapamycin dose was
reduced (3 mg/kg). Moreover, brain size was also reduced
by rapamycin, as detected byMRI (6 mg/kg). Thus, alterna-
tive mTOR inhibitors with a safer profile should be consid-
ered for therapeutic drug development in epilepsy.
Several research groups have contributed to establish that
BBB dysfunction occurs in epilepsy as in multiple neuro-
logic disorders including stroke and trauma. Consequently,
blood-borne molecules enter the brain and induce an injury
response leading to pathologic changes.59–61 In particular,
Kaufer reported evidence in collaboration with Friedman
that albumin, the most abundant protein in the blood, serves
as a signaling molecule to trigger the inflammatory injury
response.59–62 Upon entering the brain after vascular dam-
age, albumin is sensed by astrocytes, apparently via binding
to transforming growth factor b receptors (TGFbRs), induc-
ing the inflammatory TGFb signaling pathway. This sets in
motion a cascade of events that represent the earliest stages
of posttraumatic pathology. Astrocytes become reactive,
releasing TGFb1 and additional pro-inflammatory cytoki-
nes that amplify the injury response throughout the brain. In
turn, subsequent widespread inflammatory signaling modu-
lates neural physiology and network connectivity, causing
changes that enhance neural excitability and ultimately lead
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to epilepsy. It has been shown that albumin activates
TGFbR in astrocytes, causing a strong pro-inflammatory
response and variety of changes within the neurovascular
unit, including: reactive gliosis, reduced K+ and glutamate
buffering, increased excitatory synaptogenesis, and aberrant
neurogenesis. These changes recapitulate the major hall-
marks of epileptogenesis that have been documented exten-
sively across animal models of epilepsy and in tissue
samples from patients, to provide a “missing link” for how
injury triggers these pathologic changes. Using bioinformat-
ics transcriptome analysis following five diverse clinical
scenarios where BBB is disrupted (stroke, trauma, chemi-
cally induced BBB disruption, and infusion of serum albu-
min or TGFb), a common transcriptional signature was
discovered dependent on albumin-induced activation of
TGFb signaling. Extracellular matrix (ECM) related–genes
emerged as a common transcriptional response, predicting
consequent degradation of ECM.62 Indeed, exposure of
brain environment to albumin led to persistent degradation
of perineuronal nets (PNNs, a protective ECM structure that
provides synaptic stability and restrict reorganization of
inhibitory interneurons) via activation of TGFb signaling.
Exposure of the brain environment to either albumin or
TGFb1 was sufficient to induce both epileptiform activity
and delayed spontaneous seizures. It is notable that blocking
TGF signaling prevented most albumin-induced hallmarks
of epileptogenesis including TGF signaling, transcriptome-
wide changes, synaptogenesis, neurogenesis, PNN degrada-
tion, hyperexcitability, and seizures.59–61,63,64 Ongoing
research evaluates the efficacy of multiple small molecules
(acting as TGFb signaling inhibitors) in blocking or revers-
ing the effects of BBB disruption on neuropathology,
excitability, epilepsy development, and cognitive functions.
The integrity and stability of PNNs in a cortical network
is essential for proper network function.65 Loss of interneu-
ron synaptic stability and precise organization can lead to
disruptions in the excitation/inhibition balance, a character-
istic of epilepsy.66,67 Recent research by Poulter’s group
supports the role of alterations to the GABAergic interneu-
ron network in the piriform cortex after kindling-induced
seizures.68 Immunohistochemistry was used to mark PNNs
and interneuron nerve terminals in control and kindled tis-
sue. PNNs were found to be significantly decreased around
parvalbumin-positive interneurons after the induction of
experimental epilepsy. In addition, a layer-specific increase
was detected in GABA-release sites originating from cal-
bindin, calretinin, and parvalbumin interneurons, implying
that there is a rewiring of the interneuronal network. This
increase in release sites was matched by an increase in
GABAergic postsynaptic densities. The observations sug-
gest that the breakdown of the PNN could be due to the
activity of matrix metalloproteinases (MMPs) and that the
prevention of PNN breakdown may reduce the rewiring of
interneuronal circuits and suppress seizures. To test this
hypothesis, doxycycline (DOX) a broad-spectrum MMP
inhibitor, was used to stabilize PNNs in kindled rats. DOX
was found to prevent PNN breakdown, reorganization of the
inhibitory innervation, and seizure genesis. These observa-
tions indicate that PNN degradation may be necessary for
the development of seizures by facilitating interneuron plas-
ticity and increased GABAergic activity. Another hypothe-
sis is that activation of MMP after kindling may also be
responsible for the conversion of pro–brain-derived neuro-
trophic factor (BDNF) to BDNF. Furthermore, BDNF has
been shown to induce the upregulation of the voltage-gated
potassium channel Kv1.6. This channel has also been shown
to be upregulated in a kindling model causing a profound
change in the excitability of parvalbumin positive interneu-
rons.69 To see if MMP inhibition altered expression of
BDNF, immunohistochemistry was performed in brain
slices from kindled rats treated with DOX. Of interest,
BDNF expression was significantly decreased in this group
in comparison to saline-treated kindled rats. It has also been
observed that BDNF treatment of cultured cortical neurons
increased the expression of Kv1.6. In kindled tissue, DOX
also normalized Kv1.6 expression.
In sum, these data show that upregulation of MMP activ-
ity after kindling has wide-ranging effects that alter innerva-
tion of interneurons as well as the excitability of a
subpopulation neurons that are important regulators of net-
work activity.
Chemokines
(Jean-Pierre Louboutin, Matteo Caleo, Yuri Bozzi,
Eleonora Palma)
These inflammatory molecules play a pivotal role in
leukocyte migration across the BBB during neuroinflamma-
tion and other neuropathologic processes.70,71 When inter-
acting with endothelial surfaces, some chemokines initiate
integrin clustering, arrest leukocytes at sites of injury, and
guide them from vascular lumen into the brain. Once within
the brain, these cells, together with microglia and astrocytes,
contribute to endothelial cell activation and further chemo-
kine secretion. CCL2 (MCP-1), CCL3 (MIP-1a), CCL4
(MIP-1b), and CCL5 (regulated on activation, normal T cell
expressed and secreted [RANTES]) induce chemotaxis of T
lymphocytes and macrophages. In vitro CCL4 and CCL5
increase T-cell adhesion to endothelial cells. CCL2 binding
to CCR2 receptor stimulates efficient migration of mono-
cytes/macrophages across brain vasculature, and CCR1 and
CCR5 receptors facilitate CCL5-driven movement of blood
mononuclear cells (PBMCs) across brain endothelium.
CCR5 is a member of the CC-chemokine receptor family
that binds several chemokines, including CCL3, CCL4, and
CCL5. It is reportedly increased in epilepsy, as are its
ligands. CCR5 is also expressed by microglia.
Louboutin et al.71–73 investigated the role of CCR5 in a
rat model of seizures provoked by intraperitoneal adminis-
tration of kainic acid (KA). Four months before KA
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injection, adult rats were given femoral intramarrow inocu-
lations of SV(RNAiR5-RevM10.AU1), which carries an
interfering RNA (RNAi) against CCR5, plus a marker epi-
tope (AU1), or its monofunctional RNAi-carrying homolog,
SV(RNAiR5). This treatment lowered expression of CCR5
in circulating PBMCs. Controls received unrelated SV
(BUGT) vector. In control rats, seizures increased the
expression of CCR5 ligands MIP-1a and RANTES in the
microvasculature and induced BBB leakage as well as
CCR-positive cells, inflammation, neuronal loss, and gliosis
in the hippocampi. Animals given either the bifunctional or
the monofunctional vector were largely protected from KA-
induced seizures, neuroinflammation, and BBB damage,
and exhibited a decreased production of MIP-1a and
RANTES, as well as reduced neuron loss. Brain CCR5
mRNA was reduced in these rats. Rats receiving RNAiR5-
bearing vectors showed far greater repair responses with
increased neuronal proliferation. Thus inhibition of CCR5
in circulating cells strongly protected rats from seizures,
BBB leakage, CNS injury, and inflammation, and facilitated
neurogenic repair. These results suggest that inhibition of
CCR5 in circulating PBMCs can decrease their interaction
with endothelial cells, thereby reducing leukocyte migration
across the BBB, and consequently neuroinflammation and
deleterious-related events.
The chemokine CCL2 is elevated in brain tissue from
patients with pharmacoresistant epilepsy.74,75 Caleo
et al.74,76 showed a crucial role for CCL2 and its receptor
CCR2 in seizure control. Mice with spontaneous seizures
and neuropathology resembling mesial temporal lobe epi-
lepsy were systemically injected with lipopolysaccharide
(LPS) to mimic a peripheral inflammatory challenge. LPS
was found to increase seizure frequency and to upregulate
the brain expression of many inflammatory proteins, includ-
ing CCL2. To test the potential role of CCL2 in seizure
exacerbation, either a CCL2 transcription inhibitor (bin-
darit) or a selective antagonist of the CCR2 receptor
(RS102895) was administered systemically. Interference
with CCL2 signaling potently suppressed LPS-induced sei-
zure worsening.76 Intracerebral administration of anti-CCL2
antibodies also abrogated LPS-mediated seizure enhance-
ment in chronically epileptic animals. These results reveal
that CCL2 is a key mediator that links peripheral inflamma-
tion with neuronal hyperexcitability.
Palma reported that cytokines and chemokines can both
influence GABAA receptor function, although they can exert
opposite effects on neuronal synaptic transmission. For
example, the chemokine fractalkine (CX3CL1) is responsible
for a positive modulation of GABAA receptor in human TLE
brain because it slows the GABAA use-dependent desensiti-
zation (i.e., rundown).75 Differently, IL-1b was found to
reduce GABAA-mediated current amplitude by activating
IRAK1 and protein kinase C.77 In both cases, the effects on
GABA currents were intrinsic characteristics of the epileptic
brain tissue, since such effects were absent in nonepileptic
controls. This observation is explained, at least in part, by an
upregulation of the cytokine/chemokine receptors. It is nota-
ble that that although in the fractalkine case the receptor’s
upregulation may represent an attempt to reduce changes
induced by epileptic insults, the IL-1b pathway actively con-
tributes to ictogenesis through the impairment of GABA-
mediated neurotransmission.77,78 Altogether, these data indi-
cate that the GABAergic system is significantly modulated
by inflammatory mediators released in epileptic foci, thus
opening a wide scenario of novel therapeutic opportunities
for controlling neuronal network hyperexcitability in epilep-
tic patients.
The Role of Peripheral Immune
Cells
(Sookyong Koh, Raymond Dingledine)
Koh’s laboratory has pioneered the characterization of
inflammatory cell infiltrates in surgically removed fresh
brain samples from pediatric patients in search for novel
therapeutic targets. They used an unbiased flow cytometric
analysis of inflammatory leukocytes in resected brain tis-
sues from pediatric patients with genetic (focal cortical dys-
plasia, FCD) or acquired (encephalomalacia) epilepsy.
They detected functionally activated lymphocytes within
the epileptogenic lesion of both patients and experimental
animals. Brain infiltration of inflammatory myeloid cells
and memory CD4+ and CD8+ T cells was observed (Koh S,
unpublished observations).77 This is in line with previous
observations in both FCD type IIb and cortical tubers in
patients with tuberous sclerosis complex patients.78-81 In
particular, T cells are concentrated in the epileptogenic
lesion and their numbers correlate positively with disease
severity, whereas numbers of regulatory T cells (Tregs)
inversely correlate (Koh S, unpublished observations). T
cell–deficient mice systemically injected with KA showed
reduction in SE severity, whereas Treg depletion heightened
seizure severity. These data support a role for peripherally
derived innate and adaptive immune responses in the patho-
genesis of intractable pediatric epilepsy favoring the clinical
development and testing of novel immunotherapeutic drugs.
Steroids that are known for their anti-inflammatory and
immuno-suppressive properties have shown efficacy in
many types of drug-resistant epilepsies. However, the sev-
ere side effects of steroids have prevented long-term or
widespread use of these drugs. Koh et al. used a two-hit
model of epileptogenesis to design novel therapies to treat
epilepsy using immunomodulatory approaches independent
of broadly acting immunosuppressive agents. They hypoth-
esize that dampening ongoing inflammation in the brain
could effectively reduce unprovoked recurrent seizures in
the absence of systemic immunosuppression. Previous
work by Miller’s lab documented the success of using
biodegradable nanoparticles formulated from the U.S.
Food and Drug Administration (FDA)–approved
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biopolymer poly(lactide-co-glycolide) (PLG) to treat a
variety of inflammatory/immune-mediated disease in ani-
mal models (Koh S, personal communication).82 Miller’s
lab has also demonstrated that supplementation of autolo-
gous natural regulatory T cells (nTregs) significantly
reduces disease severity in multiple animal models of mul-
tiple sclerosis.79,80 In the two-hit model of early life sei-
zures, treatment with PLG nanoparticles induced leukocyte
sequestration in the spleen, thereby reducing their brain
infiltration, and prevented the priming effect of early life
seizures for heightened seizure susceptibility in adulthood.
Similarly, infusion of nTregs after the first seizure blocked
the priming effect of early life seizures (Koh S, unpub-
lished observations). Inhibition of long-term effects of
early seizure priming was attained also by directly block-
ing inflammatory microglia in the hippocampus with
minocycline.81 The characterization of the adaptive immu-
nity responses in epilepsy and the effects of restriction of
brain infiltration by inflammatory leukocyte subsets on sei-
zures represent major steps forward in our understanding
of epilepsy pathophysiology.
Dingledine et al. examined the cellular components of
innate immune inflammation in the early days following
kainate- or pilocarpine-induced SE in adult mice by dis-
criminating microglia versus brain-infiltrating mono-
cytes.82 CCR2+ monocytes invade hippocampus between 1
and 3 days after SE. In contrast, at odds with early life sei-
zures, only occasional CD3+ T lymphocytes were encoun-
tered 3 days post-SE in adult animals. The chemokine
CCL2, a ligand for CCR2, was expressed in perivascular
macrophages and microglia one day after SE. Four days
after SE the induction of the pro-inflammatory cytokine
IL-1b was greater in fluorescence-activated cell sorting
(FACS)–isolated microglia than in brain monocytes. How-
ever, in WT naive mice the mRNA levels of IL-1b were
125-fold higher in circulating blood monocytes than in
resting microglia, and TNFa levels were 486-fold greater
in blood monocytes. Ccr2 KO mice displayed greatly
reduced monocyte recruitment into brain and reduced
levels of the pro-inflammatory cytokine IL-1b in hip-
pocampus after SE. This was explained by high levels of
the cytokine in circulating monocytes in WT mice, which
were prevented from entering the brain after SE in Ccr2
KO mice. These findings indicate that microglia and mono-
cytes respond differently to SE. Whereas brain-invading
monocytes show little induction of IL-1b and TNFa
mRNA in response to SE, both IL-1b and CCL2 are signif-
icantly induced in activated microglia. However, these
results also indicate that the level of IL-1b and TNFa in
circulating monocytes is much higher than that of activated
microglia. Therefore, preventing monocyte recruitment
into the brain may reduce the extent of neuroinflammation.
Mice with impaired monocyte recruitment showed acceler-
ated weight regain, reduced BBB leakage, and attenuated
neuronal damage following SE.82 These findings identify
brain-infiltrating monocytes as a myeloid cell subclass that
contributes substantially to the extent of neuroinflamma-
tion and morbidity after SE. Inhibiting brain invasion of
CCR2+ monocytes could represent a viable method for
alleviating the deleterious consequences of SE.
Conclusion and Future
Directions
Several of the inflammatory targets and pathways dis-
cussed earlier provide examples of new potential avenues
for future therapeutic approaches in epilepsy. These studies
indicate that immunomodulatory treatments alone might not
be sufficient to counteract epileptogenesis efficiently, rather
that it is likely necessary to interfere with the complex
pathophysiologic underpinnings of epileptogenesis at multi-
ple levels and in various cell types (e.g., with drug combina-
tions or complementary treatment approaches). miRNAs as
master regulators of immune responses could also represent
interesting targets for therapy. The development of miRNAs
therapy formulations that can bypass the BBB and specifi-
cally target the seizure focus represents a major challenge
for translational epilepsy research.
Despite the achievements and significant progress
reported during the Immunity and Inflammation in Epilepsy
meeting 2016 meeting, a major challenge is represented by
the translation of these experimentally successful anti-icto-
genic or disease-modifying targets into clinically effective
human therapies. This translation requires intense and col-
laborative efforts by both preclinical and clinical scientists
as well as industry partners. Future success of drug develop-
ment should be based on more coordinated experimental
and clinical trial designs guided by relevant biomarkers that
may be used to monitor epileptogenesis.
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